D Mancama

Summary

Affiliation: King's College London
Country: UK

Publications

  1. ncbi Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response
    D Mancama
    Section of Clinical Neuropharmacology, Department of Psychological Medicine, Institute of Psychiatry, DeCrespigny Park, Denmark Hill, London, England
    Am J Med Genet B Neuropsychiatr Genet 144:849-53. 2007
  2. ncbi Genetic predictors of therapeutic response to clozapine: current status of research
    Dalu Mancama
    Clinical Neuropharmacology, Institute of Psychiatry, Denmark Hill, London, UK
    CNS Drugs 16:317-24. 2002
  3. ncbi Pharmacogenomics of psychiatric drug treatment
    Dalu Mancama
    Institute of Psychiatry, Clinical Neuropharmacology, Denmark Hill, London, SE5 8AF, UK
    Curr Opin Mol Ther 5:642-9. 2003
  4. ncbi Role of pharmacogenomics in individualising treatment with SSRIs
    Dalu Mancama
    Clinical Neuropharmacology, Institute of Psychiatry, Denmark Hill, London, England
    CNS Drugs 17:143-51. 2003
  5. ncbi Pharmacogenomics--can genetics help in the care of psychiatric patients?
    A A Bolonna
    Clinical Neuropharmacology, Division of Psychological Medicine, Institute of Psychiatry, KCL, London, UK
    Int Rev Psychiatry 16:311-9. 2004
  6. ncbi Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia
    D Mancama
    Section of Clinical Neuropharmacology, Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London, England, UK
    Am J Med Genet B Neuropsychiatr Genet 119:2-6. 2003
  7. ncbi Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response
    D Mancama
    Section of Clinical Neuropharmacology, Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK
    Neurosci Lett 333:207-11. 2002
  8. ncbi Neurotransmitter receptor variants and their influence on antipsychotic treatment (Review))
    M J Arranz
    Clinical Neuropharmacology, Institute of Psychiatry, London SE5 8AF, UK
    Int J Mol Med 7:27-30. 2001
  9. ncbi Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population
    Susan Staddon
    Clinical Neuropharmacology PO51, Division of Psych Medicine, Institute of Psychiatry, KCL, Denmark Hill, London SE5 8AF, UK
    Schizophr Res 73:49-54. 2005
  10. ncbi Expression of the alpha1A-adrenergic receptor in schizophrenia
    Dan A Clark
    Clinical Neuropharmacology P051, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, United Kingdom
    Neurosci Lett 401:248-51. 2006

Detail Information

Publications11

  1. ncbi Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response
    D Mancama
    Section of Clinical Neuropharmacology, Department of Psychological Medicine, Institute of Psychiatry, DeCrespigny Park, Denmark Hill, London, England
    Am J Med Genet B Neuropsychiatr Genet 144:849-53. 2007
    ....
  2. ncbi Genetic predictors of therapeutic response to clozapine: current status of research
    Dalu Mancama
    Clinical Neuropharmacology, Institute of Psychiatry, Denmark Hill, London, UK
    CNS Drugs 16:317-24. 2002
    ....
  3. ncbi Pharmacogenomics of psychiatric drug treatment
    Dalu Mancama
    Institute of Psychiatry, Clinical Neuropharmacology, Denmark Hill, London, SE5 8AF, UK
    Curr Opin Mol Ther 5:642-9. 2003
    ..Knowledge from these studies will ultimately lead to the individualization of psychiatric drug treatment, while providing new insights into the etiology of these disorders and their future treatment...
  4. ncbi Role of pharmacogenomics in individualising treatment with SSRIs
    Dalu Mancama
    Clinical Neuropharmacology, Institute of Psychiatry, Denmark Hill, London, England
    CNS Drugs 17:143-51. 2003
    ..By comprehensively delineating these genetic components, it is envisaged that this will eventually facilitate the development of highly sensitive protocols for individualising SSRI treatment...
  5. ncbi Pharmacogenomics--can genetics help in the care of psychiatric patients?
    A A Bolonna
    Clinical Neuropharmacology, Division of Psychological Medicine, Institute of Psychiatry, KCL, London, UK
    Int Rev Psychiatry 16:311-9. 2004
    ....
  6. ncbi Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia
    D Mancama
    Section of Clinical Neuropharmacology, Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London, England, UK
    Am J Med Genet B Neuropsychiatr Genet 119:2-6. 2003
    ..These results provide evidence in support of altered muscarinic 1 receptor expression in schizophrenia, though further work is needed to corroborate these findings...
  7. ncbi Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response
    D Mancama
    Section of Clinical Neuropharmacology, Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK
    Neurosci Lett 333:207-11. 2002
    ....
  8. ncbi Neurotransmitter receptor variants and their influence on antipsychotic treatment (Review))
    M J Arranz
    Clinical Neuropharmacology, Institute of Psychiatry, London SE5 8AF, UK
    Int J Mol Med 7:27-30. 2001
    ..Recent advances indicate that this goal is achievable in the near future. The scope of this communication is to review all the recent findings in psychopharmacogenetics leading to the individualization of treatment...
  9. ncbi Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population
    Susan Staddon
    Clinical Neuropharmacology PO51, Division of Psych Medicine, Institute of Psychiatry, KCL, Denmark Hill, London SE5 8AF, UK
    Schizophr Res 73:49-54. 2005
    ..However, further replication in independent samples is required...
  10. ncbi Expression of the alpha1A-adrenergic receptor in schizophrenia
    Dan A Clark
    Clinical Neuropharmacology P051, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, United Kingdom
    Neurosci Lett 401:248-51. 2006
    ..Genotypic data for the subjects found that possession of the previously associated genotypes did not convey a difference in mRNA expression suggesting that these polymorphisms do not affect the level of transcription...
  11. ncbi Clinical applications of pharmacogenetics in psychiatry
    Susan Staddon
    Section of Clinical Neuropharmacology, Institute of Psychiatry, London SE5 8AF, UK
    Psychopharmacology (Berl) 162:18-23. 2002
    ..This review tries to summarise recent advances and provides an overview of future clinical applications...